PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions

Footnotes and References

a.assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).
1.Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clinical Pharmacology & Therapeutics 2003; 74: 150-56.[PubMed]
2.Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 27-37.[PubMed]
3.Elliott P, Dundee JW, Elwood RJ, Collier PS. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. European Journal of Anaesthesiology 1984; 1: 245-51.[PubMed]
4.Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-13.[PubMed]
5.Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. British Journal of Clinical Pharmacology 1994; 37: 221-25.[PubMed]
6.Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and Analgesia 1996; 82: 511-16.[PubMed]
7.Lamberg TS, Kivisto KT, Laitila J, Martensson K, Neuvonen PJ. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. European Journal of Clinical Pharmacology 1998; 54: 761-66.[PubMed]
8.O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, Fischer T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. British Journal of Cancer 2003; 89: 1855-59.[PubMed]
9.Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. Journal of Clinical Pharmacology 1993; 33: 1104-09.[PubMed]
10.Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clinical Pharmacology & Therapeutics 2007; 81: 679-84.[PubMed]
11.Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics 2003; 73: 264-71.[PubMed]
12.Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel-Forschung/Drug Research 1996; 46: 213-17.[PubMed]
13.Cockshott ID. Bicalutamide - Clinical pharmacokinetics and metabolism. Clinical Pharmacokinetics 2004; 43: 855-78.[PubMed]
14.Somogyi A, Muirhead M. Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics 1987; 12: 321-66.[PubMed]
15.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 47-53.[PubMed]
16.Li G, Treiber G, Meinshausen J, Wolf J, Werringloer J, Klotz U. Is cyclosporin A an inhibitor of drug metabolism? British Journal of Clinical Pharmacology 1990; 30: 71-77.[PubMed]
17.Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of Clinical Pharmacology 2003; 43: 1274-82.[PubMed]
18.Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. British Journal of Clinical Pharmacology 1983; 16: 743-46.[PubMed]
19.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 19-26.[PubMed]
20.Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1 '-hydroxylation. British Journal of Clinical Pharmacology 2000; 50: 333-37.[PubMed]
21.Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. European Journal of Clinical Pharmacology 1994; 46: 551-55.[PubMed]
22.Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC, Rogers JD. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. Journal of Clinical Pharmacology 2001; 41: 573-81.[PubMed]
Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.